Léo Aubert

Dr. Léo Aubert

Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
VBValentin Van Den Bossche
Valentin Van Den Bossche
JVJulie Vignau
Julie Vignau
EVEngy Vigneron
Engy Vigneron
IRIsabella Rizzi
Isabella Rizzi
HZHannah Zaryouh
Hannah Zaryouh
Cyril CorbetCyril Corbet
Cyril Corbet
Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent occurrence of secondary resistance mechanisms. Here we report that cetuximab-resistant HNSCC cells display a peroxisome proliferator-activated receptor alpha (PPARα)-mediated lipid metabolism reprogramming, with increased fatty acid uptake and oxidation capacities, while glycolysis is not modified. This metabolic shift makes cetuximab-resistant HNSCC cells particularly sensitive to a pharmacological inhibition of either carnitine palmitoyltransferase 1A (CPT1A) or PPARα in 3D spheroids and tumor xenografts in mice. Importantly, the PPARα-related gene signature, in human clinical datasets, correlates with lower response to anti-EGFR therapy and poor survival in HNSCC patients, thereby validating its clinical relevance. This study points out lipid metabolism rewiring as a non-genetic resistance-causing mechanism in HNSCC that may be therapeutically targeted to overcome acquired resistance to anti-EGFR therapy.

28 December 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
VGVerena Gress
Verena Gress
MRMathieu Roussy
Mathieu Roussy
LBLuc Boulianne
Luc Boulianne
MBMélanie Bilodeau
Mélanie Bilodeau
SCSophie Cardin
Sophie Cardin
SCSonia Cellot
Sonia Cellot
Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted, and highly lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of primary patient samples hamper the discovery of cell- and genotype-specific treatments. AMKL is driven by mutually exclusive chimeric fusion oncogenes in two-thirds of the cases, with CBFA2T3::GLIS2 (CG2) and NUP98 fusions (NUP98r) representing the highest-fatality subgroups. We established CD34+ cord blood–derived CG2 models (n = 6) that sustain serial transplantation and recapitulate human leukemia regarding immunophenotype, leukemia-initiating cell frequencies, comutational landscape, and gene expression signature, with distinct upregulation of the prosurvival factor B-cell lymphoma 2 (BCL2). Cell membrane proteomic analyses highlighted CG2 surface markers preferentially expressed on leukemic cells compared with CD34+ cells (eg, NCAM1 and CD151). AMKL differentiation block in the mega-erythroid progenitor space was confirmed by single-cell profiling. Although CG2 cells were rather resistant to BCL2 genetic knockdown or selective pharmacological inhibition with venetoclax, they were vulnerable to strategies that target the megakaryocytic prosurvival factor BCL-XL (BCL2L1), including in vitro and in vivo treatment with BCL2/BCL-XL/BCL-W inhibitor navitoclax and DT2216, a selective BCL-XL proteolysis-targeting chimera degrader developed to limit thrombocytopenia in patients. NUP98r AMKL were also sensitive to BCL-XL inhibition but not the NUP98r monocytic leukemia, pointing to a lineage-specific dependency. Navitoclax or DT2216 treatment in combination with low-dose cytarabine further reduced leukemic burden in mice. This work extends the cellular and molecular diversity set of human AMKL models and uncovers BCL-XL as a therapeutic vulnerability in CG2 and NUP98r AMKL.

21 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KGKatarzyna Głowacka
Katarzyna Głowacka
SISébastien Ibanez
Sébastien Ibanez
OROphélie Renoult
Ophélie Renoult
PVPerrine Vermonden
Perrine Vermonden
Maria Virginia GiolitoMaria Virginia Giolito
Maria Virginia Giolito
Olivier FeronOlivier Feron
Olivier Feron
Cancer cells in acidic tumor regions are aggressive and a key therapeutic target, but distinguishing between acid-exposed and hypoxic cells is challenging. Here, we use carbonic anhydrase 9 (CA9) antibodies to mark acidic areas in both hypoxic and respiring tumor areas, along with an HRE-GFP reporter for hypoxia, to isolate distinct cell populations from 3D tumor spheroids. Transcriptomic analysis of CA9-positive, hypoxia-negative cells highlights enriched fatty acid desaturase activity. Inhibiting or silencing stearoyl-CoA desaturase-1 (SCD1) induces ferroptosis in CA9-positive acidic cancer cells and delays mouse tumor growth, an effect enhanced by omega-3 fatty acid supplementation. Using acid-exposed cancer cells and patient-derived tumor organoids, we show that SCD1 inhibition increases acidic cancer cell reliance on external mono-unsaturated fatty acids, depriving hypoxic cells of essential resources. This bystander effect provides unbiased evidence for a lack of full overlap between hypoxic and acidic tumor compartments, highlighting a rationale for targeting desaturase activity in cancer.

16 February 2024 in EMBO Reports
Verified
Journal Article
Open access
LALéo Aubert
Léo Aubert
EBEstelle Bastien
Estelle Bastien
OROphélie Renoult
Ophélie Renoult
CGCéline Guilbaud
Céline Guilbaud
KÖKübra Özkan
Kübra Özkan
Olivier FeronOlivier Feron
Olivier Feron
Tumor acidosis is associated with increased invasiveness and drug resistance. Here, we take an unbiased approach to identify vulnerabilities of acid-exposed cancer cells by combining pH-dependent flow cytometry cell sorting from 3D colorectal tumor spheroids and transcriptomic profiling. Besides metabolic rewiring, we identify an increase in tetraploid cell frequency and DNA damage response as consistent hallmarks of acid-exposed cancer cells, supported by the activation of ATM and ATR signaling pathways. We find that regardless of the cell replication error status, both ATM and ATR inhibitors exert preferential growth inhibitory effects on acid-exposed cancer cells. The efficacy of a combination of these drugs with 5-FU is further documented in 3D spheroids as well as in patient-derived colorectal tumor organoids. These data position tumor acidosis as a revelator of the therapeutic potential of DNA repair blockers and as an attractive clinical biomarker to predict the response to a combination with chemotherapy.

1 April 2026
Verified
Thesis
Closed access
LALéo Aubert
Léo Aubert
Notre laboratoire a montré que le NGF et les neurotrophines sont des facteurs déterminants de la cancérogenèse mammaire, et plus particulièrement de la croissance et de l’invasion des cellules cancéreuses de sein. Les effets du NGF dépendent, entre autres, de l’activation du récepteur à activité tyrosine kinase TrkA. Récemment, nous avons décrit que le précurseur du NGF, le proNGF, est également produit et sécrété par les cellules cancéreuses de sein pour induire leur invasion via la formation d’un complexe sortiline/TrkA. Néanmoins, les différentes signalisations induites par le NGF et le proNGF ne sont pas encore parfaitement décryptées dans le cancer du sein. Au cours de ma thèse, j’ai démontré que le NGF et le proNGF induisent des complexes de récepteurs distincts. Ainsi, alors que le NGF conduit à la formation d’un complexe membranaire TrkA/CD44, le proNGF recrute quant à lui la sortiline, TrkA et EphA2. En outre, les études in vivo, réalisées dans un modèle de souris SCID, montrent que la croissance tumorale est dépendante de la formation de ces complexes. Ainsi, l’administration conjointe d’un inhibiteur de l’activité kinase de TrkA (CEP-701) et d’un ARN interférent dirigé soit contre CD44, soit contre EphA2, diminue significativement le volume tumoral en comparaison à l’utilisation en monothérapie du CEP-701 ou d’un siEphA2 ou du siCD44. L’ensemble de mes résultats a permis d’approfondir les mécanismes d’action du NGF et de son précurseur dans les cellules cancéreuses mammaires et suggère l’existence de mécanismes de résistance à travers les coopérations TrkA/CD44 et TrkA/EphA2, ouvrant ainsi l’opportunité à de nouvelles stratégies thérapeutiques dans les cancers.